With a significant economic value, pepper (Capsicum annuum L., Solanaceae) represents a major vegetable crop worldwide. Simple sequence repeats (SSR) markers and expressed sequence tags (EST-SSR) are powerful tools for genetic studies and the breeding of pepper. In this study, the genetic variability among local pepper species was assessed by using 8 EST/SSR markers. The pepper varieties were collected locally, based on old sorts, hybrids, and sorts found in markets, with a total of 14 pepper varieties.  Mean expected heterozygosity (He) ranged from s 0.30 to 0.83 in the populations studied, whereas the mean polymorphic information content (PIC) was 0.62. The average polymorphic number of alleles per primer was 2.5 per locus. The genetic relationships among the populations revealed by Neighbor-Joining dendrogram showed a clear clustering to three sub-populations making distinct clusters.  As expected, all local varieties make up one cluster, together with the hybrid Istra, concluding that this hybrid evolved from the cross-breeding of local varieties.  These results indicate and confirm the regional and physiological differences between the pepper sorts.

The ability to insert a gene into a plant’s nuclear or chloroplast genome enables the transformation of higher plants (e.g. tobacco, Arabidopsis thaliana, potato, tomato, and banana) into Bioreactors for the production of plant-derived pharmaceuticals. Biopharmaceuticals are generally produced on a commercial basis by scale fermentation in bacteria, yeast, or animal cells. Several plant-derived pharmaceuticals have undergone clinical trials and are close to market authorization, with antibodies and vaccines being the front runners. Plant-derived vaccines have been produced using recombinant plant viruses as transgenic expression vectors and Agrobacterium tumefaciens transformation systems. During the last decade, several efficient plant-based expression systems have been examined, and more than 100 recombinant proteins, including plant-derived vaccine antigens. Besides, regulatory protocols are slowing down production. Industry requirements and public acceptance of the technology are important aspects in establishing successful products. This paper reviews the current status of development in the area of biopharmaceuticals and vaccines produced from transgenic plants.